{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:10:11Z","timestamp":1792131011552,"version":"4.4.0"},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T00:00:00Z","timestamp":1534291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this study was to evaluate prespecified and post hoc analyses in<jats:styled-content style=\"fixed-case\">RENEW<\/jats:styled-content>subgroups to identify participants more likely to benefit from opicinumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">RENEW<\/jats:styled-content>assessed the efficacy\/safety of opicinumab versus placebo in participants with a first unilateral acute optic neuritis (<jats:styled-content style=\"fixed-case\">AON<\/jats:styled-content>) episode. Difference in visual evoked potential (<jats:styled-content style=\"fixed-case\">VEP<\/jats:styled-content>) latency of the affected eye at 24\u00a0weeks versus the fellow eye at baseline was the primary endpoint. Interactions between the primary endpoint and prespecified baseline variables (including age, timing of treatment initiation, and visual impairment) using the median as cut\u2010off were evaluated in the per protocol population using analysis of covariance (<jats:styled-content style=\"fixed-case\">ANCOVA<\/jats:styled-content>); subgroups based on preexisting brain T2 lesion volume were also analyzed. Interactions between the primary endpoint and retinal ganglion cell layer\/inner plexiform layer (<jats:styled-content style=\"fixed-case\">RGCL<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">IPL<\/jats:styled-content>) and retinal nerve fiber layer (<jats:styled-content style=\"fixed-case\">RNFL<\/jats:styled-content>) thickness were assessed post hoc as was weight gain by treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment benefit of opicinumab (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>33) over placebo (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>36) on the primary endpoint was greatest in participants older than the median age at baseline (\u226533\u00a0years); the difference versus placebo for baseline age \u226533\u00a0years was \u221214.17\u00a0msec [<jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.01] versus \u22120.89\u00a0msec for baseline age &lt;33\u00a0years, [<jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.87]). Post hoc analysis showed that<jats:styled-content style=\"fixed-case\">VEP<\/jats:styled-content>latency recovery was significantly associated with less<jats:styled-content style=\"fixed-case\">RGCL<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">IPL<\/jats:styled-content>thinning (<jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.0164), occurring early on.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>Age was the strongest prespecified baseline characteristic associated with a treatment effect of opicinumab. A strong association between<jats:styled-content style=\"fixed-case\">VEP<\/jats:styled-content>latency recovery at week 24 and early<jats:styled-content style=\"fixed-case\">RGCL<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">IPL<\/jats:styled-content>preservation was observed.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acn3.620","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T04:09:32Z","timestamp":1534392572000},"page":"1154-1162","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Predictors of response to opicinumab in acute optic neuritis"],"prefix":"10.1002","volume":"5","author":[{"given":"Diego","family":"Cadavid","sequence":"first","affiliation":[{"name":"Biogen Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Balcer","sequence":"additional","affiliation":[{"name":"Departments of Neurology, Population Health, and Ophthalmology New York University School of Medicine New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Galetta","sequence":"additional","affiliation":[{"name":"Departments of Neurology, Population Health, and Ophthalmology New York University School of Medicine New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[{"name":"Department of Neurology Medical Faculty Heinrich\u2010Heine\u2010Universit\u00e4t D\u00fcsseldorf D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[{"name":"MS Center Dresden Center of Clinical Neuroscience University Hospital Carl Gustav Carus Dresden University of Technology Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludo J.","family":"Vanopdenbosch","sequence":"additional","affiliation":[{"name":"Department of Neurology AZ Sint\u2010Jan Brugge\u2010Oostende AV Brugge Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Leocani","sequence":"additional","affiliation":[{"name":"Vita\u2010Salute San Raffaele University Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[{"name":"University of Ottawa and the Ottawa Hospital Research Institute Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon T.","family":"Plant","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana Lizrova","family":"Preiningerova","sequence":"additional","affiliation":[{"name":"Charles University in Prague Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Focke","family":"Ziemssen","sequence":"additional","affiliation":[{"name":"Center for Ophthalmology Eberhard Karls University of Tuebingen Tuebingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Massacesi","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Drugs and Child's Health University of Florence Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chai","sequence":"additional","affiliation":[{"name":"Biogen Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[{"name":"Biogen Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the RENEW Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,8,15]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"1017","article-title":"The National Eye Institute Visual Function Questionnaire: experience of the ONTT","volume":"41","author":"Cole SR","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000135"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)75429-7"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-1313.2007.00501.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510371408"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.11.002"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0068-8"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000018"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1664"},{"issue":"10","key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"P1.186","DOI":"10.1212\/WNL.82.10_supplement.P1.186","article-title":"Blocking LINGO\u20101 does not affect inflammatory markers in the cerebrospinal fluid of individuals with multiple sclerosis","volume":"82","author":"Ranger ARS","year":"2014","journal-title":"Neurology"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30377-5"},{"key":"e_1_2_8_13_1","volume-title":"Evoked potentials in clinical testing","author":"Halliday AM","year":"1993"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1364\/OE.18.019413"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-11762"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-7434"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2010.07.026"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a020594"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2172"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00874118"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.51.10.1253"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2011.11.019"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32346-2"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00004-1"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000629"},{"issue":"10","key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"P3.154","DOI":"10.1212\/WNL.82.10_supplement.P3.154","article-title":"Efficacy and safety of anti LINGO\u20101 for the treatment of relapsing forms of multiple sclerosis: design of the phase 2 SYNERGY trial","volume":"82","author":"Cadavid D","year":"2014","journal-title":"Neurology"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facn3.620","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T07:50:52Z","timestamp":1720511452000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,15]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/acn3.620"],"URL":"https:\/\/doi.org\/10.1002\/acn3.620","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,15]]},"assertion":[{"value":"2018-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}